Interactions between protease inhibitors and acid-reducing agents: A systematic review

HIV Medicine

Volumn 8, Issue 6, 2007, Pages 335-345

  Béïque, Lizanne ^a,b   Giguere P ^a,b   La Porte, C ^a,b   Angel, J ^a,b  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Acid reducing agents; Antacids; Histamine 2 receptor antagonists; Protease inhibitors; Proton pump inhibitors

Indexed keywords

ALUMINUM MAGNESIUM HYDROXIDE; AMPRENAVIR; AMPRENAVIR PHOSPHATE; ANTACID AGENT; ANTIRETROVIRUS AGENT; ATAZANAVIR; CIMETIDINE; DARUNAVIR; DIDANOSINE; ESOMEPRAZOLE; FAMOTIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; INDINAVIR; LANSOPRAZOLE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; MAGNESIUM HYDROXIDE; NELFINAVIR; NIZATIDINE; OMEPRAZOLE; PANTOPRAZOLE; PROTEINASE INHIBITOR; PROTON PUMP INHIBITOR; RABEPRAZOLE; RANITIDINE; RITONAVIR; SAQUINAVIR; TENOFOVIR; TIPRANAVIR; UNINDEXED DRUG;

AREA UNDER THE CURVE; CLINICAL PROTOCOL; COMBINATION CHEMOTHERAPY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG MEGADOSE; DRUG METABOLISM; DRUG MONITORING; DRUG POTENTIATION; DYSPEPSIA; EMBASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MEDLINE; MONOTHERAPY; PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE;

ANTACIDS; DRUG INTERACTIONS; FEMALE; HISTAMINE ANTAGONISTS; HIV INFECTIONS; HUMANS; MALE; PROTEASE INHIBITORS; PROTON PUMP INHIBITORS;

EID: 34547438657     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2007.00482.x     Document Type: Review

References (54)

1. Burgos A, Garrido J. Use of acid reducing agents among HIV infected patients receiving antiretrovirals in Spain. 10th European AIDS Conference. Dublin, Ireland, November 2005 [Abstract PE4.3/5].
2. Luber A, Garg V, Gharakhanian S, Team VHP. Survey of medication used by HIV-infected patients that affect gastrointestinal acidity and potential for negative drug interactions with HAART. 7th International Congress on Drug Therapy in HIV Infection. Glasgow, UK, November 2004 [Abstract 206].
3. van Lunzen J, Arasteh K, Schuermann D. High proportion of patients taking concomitant protease-inhibitor containing HAART and gastric pH-modifying agents - the Northern German HAART pH Blocker Survey. 10th European AIDS Conference. Dublin, Ireland, November 2005 [Abstract PE4.3/ 14].
4. Fulco PP, Vora UB, Bearman GM. Acid suppressive therapy and the effects on protease inhibitors. Ann Pharmacother 2006; 40: 1974-1983.
5. Agarwala S, Gray K, Eley T, Wang Y, Hughes E, Grasela D. Pharmacokinetic interaction between atazanavir and omeprazole in healthy subjects. 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment. Rio de Janeiro, Brazil, 24-27 July 2005 [Abstract WePe3.3C08].
6. Baldwin JR, Boron MT, Wang Y, Schneck DW, Hopkins NK. Effects of food and antacid on bioavailability of the protease inhibitor PNU-140690 in healthy volunteers. 5th Conference on Retroviruses and Opportunistic Infections. Chicago, IL, 1-5 February 1998 [Abstract 649].
7. Cato A, Qian J, Hsu A et al. Pharmacokinetic interaction between ritonavir and didanosine when administered concurrently to HIV-infected patients. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 18: 466-472.
8. Chan-Tak KM, Edozien A. Ritonavir-boosted atazanavir may be efficaceous in HIV-infected patients concurrently receiving omeprazole. Clin Infect Dis 2006; 42: 1344.
9. Fang A, Damle BD, Labadie R, Crownover P, Hewlett D, Glue P. Omeprazole (OME) significantly decreases nelfinavir (NFV) systemic exposure in healthy subjects. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, 27-30 September 2006 [Abstract 384].
10. Kakuda TN, Falcon RW. Effect of food and ranitidine on saquinavir pharmacokinetics and gastric pH in healthy volunteers. Pharmacotherapy 2006; 26: 1060-1068.
11. Kiser JJ, Lichtenstein KA, Anderson PL, Fletcher CV. Effects of esomeprazole on the pharmacokinetics of atazanavir and fosamprenavir in a patient with human immunodeficiency virus infection. Pharmacotherapy 2006; 26: 511-514.
12. Luber A, Brower R, Peloquin C, Frank I. Steady state pharmacokinetics of QD fosamprenavir/ritonavir(r) and atazanavir/r alone and in combination with 20 mg of omeprazole (OMP) in healthy volunteers. 7th International Workshop on Clinical Pharmacology of HIV Therapy. Lisbon, Portugal, 20-22 April 2006 [Abstract 36].
13. O'Mara E, Mummaneni V, Randall D et al. BMS-232632: A summary of multiple dose pharmacokinetic, food effect and drug interaction studies in healthy subjects. 7th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, 30 January-2 February 2000 [Abstract 504].
14. Poirier J, Guiard-Schmid J, Bonnard P et al. Proton pump inhibitors do not decrease atazanavir trough plasma concentrations in HIV-infected patients treated with ritonavir boosted atazanavir regimen (300/100 mg qd). 45th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, 16-19 December 2005 [Abstract H1895].
15. Sahloff EG, Duggan JM. Clinical outcomes associated with concomitant use of atazanavir and proton pump inhibitors. Ann Pharmacotherapy 2006; 40: 1731-1736.
16. Shelton MJ, Mei H, Hewitt RG, Defrancesco R. If taken 1 hour before indinavir (IDV), didanosine does not affect IDV exposure, despite persistent buffering effects. Antimicrob Agents Chemother 2001; 45: 298-300.
17. Hunt RH. Importance of pH control in the management of GERD. Arch Intern Med 1999; 159: 649-657.
18. Maton PN, Burton ME. Antacids revisited, a review of their clinical pharmacology and recommended therapeutic use. Drugs 1999; 57: 855-870.
19. Blum RA, Shi H, Karol MD, Greski-Rose PA, Hunt RH. The comparative effects of lansoprazole, omeprazole, and ranitidine in suppressing gastric acid secretion. Clin Ther 1997; 19: 1013-1023.
20. Spencer CM, Faulds D. Esomeprazole. Drugs 2000; 60: 321-329.
21. Bristol-Myers Squibb Canada. Atazanavir Product Monograph. Montreal, Quebec, Canada: Bristol-Myers Squibb Canada, 2006.
22. Sahai J, Gallicano K, Swick L et al. Reduced plasma concentrations of antituberculosis drugs in patients with HIV infection. Ann Intern Med 1997; 127: 289-293.
23. Chong E, Ensom MH. Pharmacogenetics of the proton pump inhibitors: A systematic review. Pharmacotherapy 2003; 23: 460-471.
24. Robinson M, Horn J. Clinical pharmacology of proton pump inhibitors: what the practising physician needs to know. Drugs 2003; 63: 2739-2754.
25. Welage LS. Pharmacologic properties of proton pump inhibitors. Pharmacotherapy 2003; 23: 74S-80S.
26. Thomson Micromedex. Micromedex Healthcare Series [Computer Program]. Greenwood Village, CO: Thomson Micromedex, 1974-2004.
27. Back D, Gibbons S, Khoo S. An update on therapeutic drug monitoring for antiretroviral drugs. Ther Drug Monit 2006; 28: 468-473.
28. la Porte CJL, Back DJ, Blaschke T et al. Updated guidelines to perform therapeutic drug monitoring for antiretroviral agents. Rev Antiviral Ther 2006; 3: 4-14.
29. Agarwala S, Gray K, Wang Y, Grasela D. Pharmacokinetic effect of omeprazole on atazanavir co-administered with ritonavir in healthy subjects. 12th Conference on Retroviruses and Opportunistic Infections. Boston, MA, 22-25 February 2005 [Abstract 658].
30. Sekar V, Hoetelmans R, De Marez T et al. Pharmacokinetics of TMC114: effect of omeprazole and ranitidine. 6th International Workshop on Clinical Pharmacology in HIV Therapy. Quebec City, Canada, 28-30 April 2005 [Abstract 17].
31. Shelton MJ, Ford SL, Borland J et al. Coadministration of esomeprazole with fosamprenavir has no impact on steady-state plasma amprenavir pharmacokinetics. J Acquir Immune Defic Syndr 2006; 42: 61-67.
32. Ford SL, Wire MB, Lou Y, Baker KL, Stein DS. Effect of antacids and ranitidine on the single-dose pharmacokinetics of fosamprenavir. Antimicrob Agents Chemother 2005; 49: 467-469.
33. Klein C, Chiu YL, Cai Y et al. Lack of effect of acid reducing agents on the pharmacokinetics of lopinavir/ritonavir tablet formulation. 13th Conference on Retroviruses and Opportunistic Infections. Denver, CO, 5-8 February 2006 [Abstract 578].
34. Winston A, Back D, Fletcher C et al. Effect of omeprazole on the pharmacokinetics of saquinavir-500 mg formulation with ritonavir in healthy male and female volunteers. AIDS 2006; 20: 1401-1406.
35. Pfizer Canada Inc. Nelfinavir Product Monograph. Kirkland, Quebec, Canada: Pfizer Canada Inc, 2004: 58.
36. van Heeswijk R, Sabo JP, Cooper C et al. The pharmacokinetic interaction between tipranavir/ritonavir 500 mg/200 mg bid (tipranavir/r) and atorvastatin, antacid and CYP3A4 in healthy volunteers. 5th International Workshop on Clinical Pharmacology in HIV Therapy. Rome, Italy, 1-3 April 2004 [Abstract 5.2].
37. Agarwala S, Eley T, Villegas C et al. Pharmacokinetic effect of famotidine on atazanavir with and without ritonavir in healthy subjects. 6th International Workshop on Clinical Pharmacology of HIV Therapy. Quebec City, Canada, 28-30 April 2005 [Abstract 11].
38. Tomilo DL, Smith PF, Ogundele AB et al. Inhibition of atazanavir oral absorption by lansoprazole gastric acid suppression in healthy volunteers. Pharmacotherapy 2006; 26: 341-346.
39. Hugen PWH, Burger DM, ter Hofstede HJM, Koopmans PP. Concomitant use of indinavir and omeprazole: Risk of antiretroviral subtherapy. AIDS 1998; 12 (Suppl. 4): S29.
40. Rublein JC, Donovan BJ, Hollowell SB et al. Effect of omeprazole on the plasma concentrations of indinavir in HIV-negative subjects. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, 14-17 September 2003 [Abstract A-1611].
41. Boffito M, Carriero P, Trentini L et al. Pharmacokinetics of saquinavir co-administered with cimetidine. J Antimicrob Chemother 2002; 50: 1081-1084.
42. Tibotec. TMC114 Investigator's Brochure. Co Cork, Ireland: Tibotec, 2006: 213.
43. Agarwala S, Persson A, Eley T et al. Effect of famotidine 20- and 40-mg dosing regimens on the bioavailability of atazanavir with ritonavir in combination with tenofovir in healthy subjects. 14th Conference on Retroviruses and Opportunistic Infections. Los Angeles, CA, 25-28 February 2007 [Abstract 568].
44. Winston A, Bloch M, Carr A et al. Atazanavir trough plasma concentration monitoring in a cohort of HIV-1-positive individuals receiving highly active antiretroviral therapy. J Antimicrob Chemother 2005; 56: 380-387.
45. Guiard-Schmid JB, Poirier JM, Bonnard P et al. Proton pump inhibitors do not reduce atazanavir concentrations in HIV-infected patients treated with ritonavir-boosted atazanavir. AIDS 2005; 19: 1937-1938.
46. Antoniou T, Yoong D, Beique L et al. Impact of acid-suppressive therapy on virologic response to atazanavir-based regimens in antiretroviral-experienced patients: A case series. J Acquir Immune Defic Syndr 2005; 39: 126-128.
47. Chang J, Towner W, Kerrigan HL, Wang L. Evaluation of concomitant use of protease inhibitor (PI)-atazanavir (ATV) with proton pump inhibitor (PPI). 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment. Rio de Janeiro, Brazil, July 2005 [Abstract WePe3.3C04].
48. Furtek KJ, Crum NF, Olson PE, Wallace MR. Proton pump inhibitor therapy in atazanavir-treated patients: Contraindicated? J Acquir Immune Defic Syndr 2006; 41: 394-396.
49. Khanlou H, Farthing C. Co-administration of atazanavir with proton-pump inhibitors and H2 blockers. J Acquir Immune Defic Syndr 2005; 39: 503.
50. Kosel BW, Storey SS, Collier AC. Lack of interaction between atazanavir and lansoprazole. AIDS 2005; 19: 637-638.
51. Burger DM, Hugen PW, Kroon FP et al. Pharmacokinetic interaction between the proton pump inhibitor omeprazole and the HIV protease inhibitor indinavir. AIDS 1998; 12: 2080-2082.
52. Bristol-Myers Squibb Canada. Didanosine Product Monograph. Montreal, Quebec, Canada: Bristol-Myers Squibb Canada, 2005: 47.
53. Merck Frosst Canada Ltd. Indinavir Product Monograph. Kirkland, Quebec, Canada: Merck Frosst Canada Ltd, 2006: 24.
54. Bertz R, Yi-Lin C, Naylor C, Luff K, Brun SC. Lack of effect of gastric acid reducing agents on lopinavir/ritonavir plasma concentrations in HIV-infected patients. Seventh International Congress on Drug Therapy in HIV Infection. Glasgow, UK, November 2004 [Abstract 279].